Tuesday - December 23, 2025
Padcev Plus Keytruda Significantly Improves Survival for Patients With Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 18, 2025
NEW YORK, Dec. 18 -- Pfizer, a pharmaceutical company, issued the following news release on Dec. 17, 2025:

* * *

PADCEV(TM) Plus Keytruda(R) Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

* PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products